SpringWorks Therapeutics, Inc.

    SpringWorks Therapeutics, Inc.

    NNASDAQ:SWTX
    - -
    USD
    - -
    - -
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    0.81
    - -
    - -
    0.09
    - -
    2.95
    Basic EPS, GAAP
    - -
    -0.8
    -4.39
    -1.05
    -3.59
    -5.21
    -5.15
    - -
    -3.41
    Free Cash Flow per Basic Share
    - -
    -0.65
    -3.57
    -0.74
    -2.64
    -3.03
    -3.53
    - -
    -2.29
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    - -
    -1.01
    -5.5
    -2.74
    -6.03
    -10.69
    -14.18
    - -
    -16.61
    Tangible Book Value per Share
    - -
    -0.96
    24.26
    12.87
    8.71
    10.47
    9.74
    - -
    5.61
    Basic Weighted Avg Shares
    - -
    22
    13
    43
    48
    53
    63
    - -
    74
    Sales/Revenue/Turnover
    - -
    - -
    - -
    35
    - -
    - -
    5
    192
    220
    Operating Margin (%)
    - -
    - -
    - -
    -132.35
    - -
    - -
    -6,297.28
    -145.17
    -120.52
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    1
    2
    3
    4
    Net Income, GAAP
    - -
    -18
    -58
    -46
    -174
    -277
    -325
    -258
    -254
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    -130.21
    - -
    - -
    -5,968.5
    -134.73
    -115.6
    Working Capital
    10
    43
    319
    496
    353
    549
    423
    280
    274
    LT Debt
    - -
    - -
    - -
    1
    - -
    5
    6
    6
    6
    Total Equity
    -3
    -19
    322
    557
    422
    558
    626
    481
    417
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    ST Debt
    1
    2
    2
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    6
    6
    6
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    74
    74
    75
    Market Capitalization
    2,373
    2,675
    3,284

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    Total Current Assets
    435
    380
    356
    Cash, Cash Equivalents & STI
    377
    308
    288
    Accounts Receivable, Net
    33
    46
    40
    Inventories
    10
    10
    12
    Total Current Liabilities
    71
    100
    82
    Payables & Accruals
    49
    67
    65
    ST Debt
    1
    2
    2
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    13.99%
    -23.17%
    Free Cash Flow
    - -
    63.09%
    -13.89%
    Net Income, GAAP
    - -
    63.17%
    -20.6%
    Sales/Revenue/Turnover
    - -
    - -
    3,417.33%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    5
    5
    2024
    21
    60
    49
    62
    192
    2025
    49
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -1.18
    -1.25
    -1.27
    - -
    -5.15
    2024
    -1.18
    -0.54
    -0.72
    - -
    - -
    2025
    -1.11
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

    • globenewswire.com

      SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

    • globenewswire.com

      European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

    • globenewswire.com

      European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

    • seekingalpha.com

      Immunome: SpringWorks Buyout Informs The Potential Upside Here

    • globenewswire.com

      European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

    • globenewswire.com

      European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

    • businesswire.com

      Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business

    • globenewswire.com

      SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

    • businesswire.com

      SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

    • zacks.com

      SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

    • globenewswire.com

      SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

    • zacks.com

      SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

    • businesswire.com

      SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

    • zacks.com

      Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

    • prnewswire.com

      SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

    • prnewswire.com

      ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

    • businesswire.com

      Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

    • investopedia.com

      Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

    • businesswire.com

      SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders